COMPARISON OF MIRABEGRON, SOLIFENACIN AND TAMSULOSIN IN RELIEVING URETERAL STENT RELATED SYMPTOMS:A DOUBLE BLINDED RANDOMIZED CONTROL TRIAL - MIRASOTA

Post Graduate Institute of Medical Education and Research0 个研究点目标入组 150 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•All patients above 18 years of age undergoing ureteral stent placement following any of the following surgeries/ procedures shall be enrolled in the study
•1.Ureteroscopic lithotripsy (URSL)
•2.Retrograde Intra-renal surgery (RIRS)
•3.Percutaneous nephrolithotomy (PCNL)
•4.Robot-assisted/ laparoscopic pyeloplasty
•5.Extracorporeal shock wave lithotripsy (ESWL)

•1.Concomitant use of alpha blockers, anticholinergics, calcium channel blockers, corticosteroids and analgesics
•2.Patients with long term indwelling ureteral stent prior to surgery ( > 4 weeks)
•3.Patients undergoing open ureteral surgery
•4.Patients with Overactive Bladder, Benign prostatic hyperplasia (IPSS score ï?³8), and Neurogenic bladder
•5.Patients with pre-operative untreated Urinary tract infection (UTI)
•6.Pregnant or breast feeding women
•7.Placement of bilateral ureteral stents
•8.Patients with moderate or severe cardiovascular/cerebrovascular disease, severe uncontrolled hypertension or hepatic dysfunction
•9.Patients with incomplete clearance of calculi following surgery
•10.Patients with prior history of pelvic surgery or irradiation
•11.Patients with prior history of bladder or prostatic surgery
•12.Patients with other acute medical conditions that might influence the USSQ pain index
•13.Any intra-operative event or surgeonâ??s discretion necessitating retention of ureteral stent in situ for more than 6 weeks
•14.Incomplete clearance of calculus after 2 cycles of ESWL

发起方

Post Graduate Institute of Medical Education and Research